SMMT (Summit Pharma) Earnings per share growth rate in current year

Official company branding of Summit Therapeutics (SMMT)

The shift in year-over-year EPS figures helps assess the development of the biopharmaceutical network of Summit Therapeutics (SMMT), which creates unique oncology drugs and closed medical hubs. The company's economic moat is expanding due to patents for ivonescab, and 26.80 reflects the latest level of this metric. The reliability of drug delivery is ensured by a strict temperature regime, which requires expenditures but guarantees product quality.

summittxinc.com (SMMT): Net earnings per share growth this year from 07/04/2022 to 11/13/2026

Analytical breakdowns and data insights for company Summit Therapeutics (SMMT)

- current price and projected stock value:
Quote Chart Summit Therapeutics plc|SMMT - Analyst Consensus Forecast
- business market valuation indicators:
Market Value Summit Pharma|SMMT - Enterprise Value
- balance sheet equity data:
Accounting Value per Share Summit Therapeutics|SMMT - Company Net Assets|Market Cap to Book Value Multiple summittxinc.com|SMMT - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Capital Coefficient Summit Therapeutics|SMMT - Long-Term Debt to Equity|Current Liabilities to Capital summittxinc.com|SMMT - Company Debts|Debt to Book Value Ratio Summit Pharma|SMMT - Company Long-Term Debt|Short-Term Debt Volume Summit Therapeutics|Interim Coverage Ratio summittxinc.com
- net income and valuation ratios data:
SMMT - Net Income|Projected Future Earnings Summit Therapeutics|SMMT - Price to Earnings Ratio|Projected Price to Earnings Summit Pharma|SMMT - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Summit Pharma|SMMT - Operating profit EBITDA|Net earnings per share for the last four quarters Summit Therapeutics|SMMT - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months summittxinc.com|SMMT - Net earnings per share growth this year|Expected earnings per share trend next year Summit Therapeutics
Basic company analysis:Summit Therapeutics plc
Mass-produced product of Summit Therapeutics Inc

This indicator measures the year-over-year dynamics of net earnings per share, allowing for an assessment of business scaling rates and capital management efficiency. By analyzing the annual trajectory of earnings per share, an investor can benchmark the financial progress of Summit Therapeutics (SMMT) against the market, evaluating how the commercialization of Ivonescimab and the success of clinical trials are transforming the development stage into actual revenue.

Main competitors

Earnings per share trend in current year MRNA (Moderna Inc)|PCVX (Vaxcyte Corp) - Earnings growth in current year|Earnings per share growth rate in current year Tarsus Corp TARS|Earnings growth in current year CRMD|Net earnings per share growth this year serestherapeutics.com MCRB|Spero Therapeutics, Inc. - Net earnings per share growth this year|Net earnings per one share growth for the current year SCYX (SCYNEXIS Inc)|AN2 Bio - Earnings growth in current year|Expected net earnings per share growth this year PolyPid Ltd. PYPD|LakeShore Biopharma Co. (LSB) - Earnings per share growth in current year|Earnings per share growth rate in current year Iterum Therapeutics (ITRM)|Earnings per share growth in current year BiomX Inc|Earnings per share growth this year SNGX (BioPharma Bio)|Earnings per share growth in current year 60 Degrees Pharmaceuticals (SXTP)|Expected net earnings per share growth this year oragenics.com|Earnings per share growth in current year OpGen, Inc. OPGN